OctoPlus signs service contract with Axentis Pharma
OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, Axentis Pharma AG. The undisclosed contract value contributes to OctoPlus' annual revenues, for which the Company reiterates its guidance of € 19 million.
Under the contract terms, OctoPlus will perform process development and clinical manufacturing of Axentis Pharma's lead product, which is an inhalable liposomal formulation of tobramycin for the treatment of cystic fibrosis.
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.